An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)

Trial Profile

An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Leber congenital amaurosis; Retinitis pigmentosa
  • Focus Therapeutic Use
  • Sponsors QLT
  • Most Recent Events

    • 12 Sep 2014 Results published in the Media Release and presented at the 47th Annual Scientific Meeting of The Retina Society.
    • 27 Aug 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2011-004214-42).
    • 25 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top